Aranesp® Improves Hemoglobin Levels in Lung Cancer Patients
According to results from a Phase III trial, the use of Aranesp® (darbepoetin alfa) in patients with small cell lung cancer (SCLC) being treated with chemotherapy results in improved levels of hemoglobin without affecting progression-free survival or overall survival.
This entry was posted on Saturday, April 28th, 2007 at 12:28 am and is filed under Research, Treatment. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.